english version
Основан в 1944 году





** NOTE: TRUNCATED STORY ** FOR three months, Mail writer Melanie Phillips has been investigating the MMR controversy. Here, in the last of three major articles, she examines claims that the vaccine has triggered an epidemic of autism in our children - and how the evidence is piling up that official complacency is sorely misplaced. Daily Mail via NewsEdge Corporation : ** NOTE: TRUNCATED STORY ** FOR three months, Mail writer Melanie Phillips has been investigating the MMR controversy. Here, in the last of three major articles, she examines claims that the vaccine has triggered an epidemic of autism in our children - and how the evidence is piling up that official complacency is sorely misplaced. ACCORDING to the medical establishment, the whole idea is a nonsense. The suggestion that a new autistic bowel disease is now affecting large numbers of children who were previously normal until they were vaccinated with MMR is simply not borne out by the evidence. There is, say these experts, nothing new going on. All that's happened is that a few parents are desperate to invent a reason for the appalling disorder of autism that has afflicted their children. Autism often isn't noticed until the second year of life, which happens to be the time children are vaccinated with MMR. The parents, so the experts insist, have put two and two together and made five. So it came as a bit of a shock to attend the annual meeting of the Autism Society of America in Indianapolis last June. There I discovered upwards of 1,000 parents, most of whom told the same story: that their children were developing totally normally until they had MMR, following which their skills and personalities disintegrated and they developed appalling gut problems and food intolerances. Take Jeff Sell, a Texas lawyer with eight-year-old twins, Ben and Joe. Ben was born with an autistic disorder but Joe passed all the normal milestones until he had MMR. 'Joe had an immediate reaction with epileptic seizures, very high fever, rash and vomiting the next day,' said Sell. 'We took him to the doctor and were given the standard party line. In a few months after that the language he had developed had all gone, and chronic diarrhoea set in.' Or take Liz Birt from Chicago. Her eight-year-old son Matthew passed all his developmental milestones until he had MMR and Hib (haemophilus influenza type B) vaccinations at 15 months. 'That night he had a high temperature. Seven days later he started to have severe diarrhoea and stopped sleeping at night. He would wake at 1am and be up for the rest of the night. And he started screaming. 'I was very concerned because he wasn't growing and putting on weight. A few months later he started staring at lights, not making eye contact. 'Previously, he could count to ten, say mama and dada and ball but all these words went away. Then it seemed he wasn't hearing what we were saying at all.' Despite the fact that Matthew had chronic diarrhoea, doctors dismissed his mother's concerns. But then she took him to be examined by Andrew Wakefield's team at the Royal Free Hospital, London. Wakefield is the British doctor who first raised the alarm about MMR, linking it to autism and bowel problems. His team discovered that Matthew was in constant pain from a grossly impacted and diseased bowel something he believes is directly linked to autism following MMR jabs. Other parents tell similar stories. Tanya Reubarger from Indianapolis said of her five-year-old son Nathan: 'He was a perfectly normal baby until he had his injection. 'Then he started regressing, throwing violent tantrums, beating his head on the walls, beating his hands until they bled, frantic, always crying. He was eating normally but he had constant diarrhoea. Yet no one will believe you.' In Britain, the National Autistic Society says it has not noticed more reports of regressive autism and bowel disease following MMR. But other groups say this is because parents with such experiences don't join the deeply conservative NAS because it gives them no support. Such parents say that through their children's disorder, they have met countless other couples whose autistic children similarly developed normally until MMR provoked a catastrophic regression. And they say the claim by autism experts that they simply failed to spot autistic symptoms before the vaccination is demonstrably untrue, since so many of them have video recordings of their babies before vaccination showing them to have been perfectly normal. TRACEY STEELL from Glasgow has triplet boys, now aged eight. They had finished a course of antibiotics shortly before their MMR vaccination. Until then, they had been perfectly normal babies. Within a few days of the jab, one by one all three developed high fever, started to scream uncontrollably and then stopped developing. 'They didn't play, they just lay there, all three of them,' she said. 'They stopped playing with the dog and the cat, they didn't play with their toys, they didn't cry; if you picked them up they would just stare at you.' Because they were triplets, she said, the babies were continuously monitored by the hospital for the whole of their first year of life - and the hospital found nothing abnormal about them, giving the lie to the claim that such parents fail to recognise autistic symptoms present before vaccination. Jonathan Harris of Birmingham has six children. The two eldest, Ashley, 16 and Laura, 14, were too old to have MMR, and are normal children. The next two, Thomas, 12, and Oliver, eight, did have MMR. Within a week of the jab, Oliver started to scream and his behaviour regressed: he wouldn't make eye contact, wouldn't play and started throwing things around. Thomas developed bowel problems and lost his language skills. Harris is now looking for single vaccines for his two youngest, who are four and almost three. 'Most parents of autistic children that I have met have had similar experiences to us,' he said. 'I know dozens of such families.' What no one disputes is that in both Britain and America there has been a huge rise in the numbers diagnosed with either autism or autism spectrum disorder (ASD), which covers other developmental abnormalities. And what is striking is that this rise coincided with MMR vaccination being made a legal requirement in the U.S. in 1979 and being introduced into the UK in 1989 (although some experts claim - with figures that have been contested - that autism started to rise in the UK two years before MMR was introduced). The main U.S. figures are collated in California, the state with the most advanced services and reporting system for developmental disorders. Rick Rollens is a former secretary of the California state senate whose own son developed regressive autism after his booster MMR shot. 'Something happened in 1979-80,' he says. 'The pattern changed.' And the rise seems to be accelerating. Between 1987 and 1998, the proportion of autistic people using California's services almost doubled. Between 1987 and 1998, there was a rise of 273 per cent in the number of autistic cases in the state. According to Rollens, California is now adding on average seven new autistic cases per day to its register. The figures are borne out by studies of other parts of the U.S. They correspond to UK figures too. Until recently, the rate of ASD in Britain was estimated at between 5 and 20 per 10,000. The Medical Research Council now puts it at about 70 per 10,000, or one in 166. The National Autistic Society thinks that is an underestimate. In a study, it found the rate running at one in 86 in primary schools, a staggeringly high figure. Teachers are increasingly reporting that they are finding it difficult to cope with the new phenomenon of autistic children in their classes. Nevertheless, the medical establishment has long maintained that the numbers aren't really increasing. DR ERIC FOMBONNE, the child psychiatrist and renowned autism expert who is advising the drug companies that make MMR, has pooh-poohed the California figures and said the high autism rates merely reflect wider and better diagnosis and recognition. He has been backed up by Dr Patrick Bolton, a child psychiatrist and co-director of the Autism Research Centre at Cambridge University, who says the explanation for the rise is unclear. 'It's most likely to be at least in part due to the fact that we've changed our way of defining and diagnosing autism and we are better at spotting it. We've broadened the concept.' However, last autumn a study by the University of California concluded that the huge rise in autism was real and could not be explained away by changes in diagnostic practice or classification. And even Dr Fombonne now appears to be conceding that a significant change is taking place. In a recent article, he wrote that rates for the range of autism disorders were now three to four times higher than they were 30 years ago. The parents respond with fury and incredulity to the idea that such behaviour could simply have been overlooked in the past or mistaken for something else. In the U.S., Jeff Sell's wife was a special needs teacher in Spring, Houston. 'In 1994, she knew there were three children with autism in our district,' he said. 'Now there are 83. 'Are we being told that there were previously 83 children, all screaming and rocking and head-banging, and nobody noticed them? You don't miss autism. There are just more of them.' Judith Barnard of the NAS agrees: 'We have heard from parents that huge numbers of autistic children are being identified, and it wasn't like that when they were kids. 'So we asked schools whether they felt there were more autistic children now than five years ago and two-thirds of them said yes. There is a sense that something perceptibly different is happening.' Yet the establishment points to an apparent paradox which they say undermines the claim of a link with MMR. How can this be cause and effect, they say, when the rate of autism is still rising even though MMR uptake has stayed steady (or even gone down)? The response from the Wakefield camp is that MMR is not the only cause of autism. Many other factors may be involved, such as, for example, the dramatically rising rate of food and other allergies, or the increasing burden of other vaccines administered to infants. In the U.S., many parents believe that the mercury found in some vaccines other than MMR, such as the diphtheria/polio/tetanus jab, may weaken a child's immune system so that MMR becomes the final knockout blow. Dr Jeff Bradstreet runs a clinic for autistic children in Florida. He firmly believes that MMR is a devastating factor in a wider process that impairs children's immune systems. His own son Matthew was a normal baby until his MMR jab. 'Within two weeks of receiving MMR, Hib and chickenpox, Matthew was lost,' he said. 'He had chronic diarrhoea and regressed into a world of his own. After his booster MMR jab he had seizures.' Tests revealed he had a very high level of measles virus in his spinal fluid. 'A Congressional researcher and I called paediatricians all over the country and presented the lab data and the history and asked them for their diagnosis and they all said measles and encephalopathy (brain disease). 'We said he had autistic features and they said the encephalopathy was causing the autistic features. 'There are many toxins in the environment. Ultimately, I think you have a series of wounding events and then in a weak state the child is exposed to MMR.' The theory that too many vaccines at once overload the immature immune system is - like everything else in this story - controversial. The eminent immunologist Sir Peter Lachmann says: 'There's no limit to what the immune system can take; that's what it is for. There is no evidence that three living viruses administered at the same time overloads it. I think this idea is entirely drawn out of the air.' But Professor James Oleske, a paediatric immunologist in New Jersey, says: 'It's not the number of antigens in a vaccine that's the problem - it's the fact that in preparing them for the vaccine, other things are added to make them more effective.' Wakefield believes it is particular folly to mix viruses in a vaccine since this makes them unpredictable in their effects - a view Lachmann dismisses. 'Compound viruses do not interfere with each other's responses,' Lachmann insists. Others say Lachmann is profoundly wrong. Autism expert Dr Ken Aitken says studies have shown that combining viruses does indeed alter their effects and increases the risk of adverse reactions. The Department of Health argues that the triple MMR vaccine is safer for children than single jabs, which would expose them and others to a far greater risk of measles, mumps and rubella through slow or nonexistent take-up. Because of the controversy, however, MMR take-up is down by about 10 per cent to 84 per cent, and demand for single jabs has soared. Drug manufacturers are now limiting the availability of single vaccines, with claims by campaigners that the Health Department is leaning on the companies not to supply them. The perils of making it difficult for GPs to give single jabs on the NHS were underlined last month when two private clinics were shut down after it was found that their single vaccines were either ineffective or contaminated. Dr Richard Halvorsen is a London GP and one of the few who gives single vaccine jabs on the NHS. 'The arguments against providing single vaccines are irrelevant if parents won't give their children MMR,' he said. 'It seemed an overwhelming clinical argument to offer the single vaccine. By not offering it, we were contributing to the potential epidemic of measles that the department is purportedly trying to prevent.' To which the Health Department replies: look at Japan. In 1993, Japan abandoned MMR completely after it suffered an outbreak of aseptic meningitis triggered by the Urabe strain of mumps vaccine within the triple jab. Urabe-strain MMR had been withdrawn in Britain the previous year for the same reasons (shamefully, the Health Department had known of the dangers when it was introduced) and replaced with an updated version. JAPAN, by contrast, switched entirely to single jabs. This has resulted, says the Health Department, in a measles epidemic in Japan and 79 deaths from the disease between 1992 and 1997. On the face of it, then, this seems a strong argument for sticking with MMR. But Dr Hiroki Nakatani, director of the Infectious Disease Division at Japan's Ministry of Health and Welfare, has a very different story to tell. He says that in 1989, when Japan first introduced MMR, there were 34 deaths from measles; in 1990, there were 53 deaths; in 1991, 39; and in 1992, 14. Then, in 1993, the Japanese government moved from recommending MMR to single vaccines instead. The number of deaths from measles per year has since remained at between 14 and 25. So in fact, in the years Japan was using MMR there were on average rather more deaths from measles quite apart from any deaths and serious damage done by the vaccine - than since single jabs were introduced. <> ** NOTE: This story has been truncated from its original size in order to facilitate transmission. If you need more information about this story, please contact NewsEdge Corporation at 1-800-766-4224. ** << Copyright ©2003 Financial Times Limited, All Rights Reserved >>

12 Март,2003 | Культура и вырождение - Освальд Бумке

Культура и вырождение - Освальд Бумке

12 Март,2003 | Best-selling drug should be withdrawn - coroner

THE world's best-selling antidepressant should be withdrawn from sale in the UK, a coroner said yesterday after linking the drug to the death of a retired Welsh teacher. The Western Mail via NewsEdge Corporation : THE world's best-selling antidepressant should be withdrawn from sale in the UK, a coroner said yesterday after linking the drug to the death of a retired Welsh teacher. Geraint Williams added his voice to a growing body of health experts concerned about a link between Seroxat and suicide after hearing how Colin Whitfield killed himself just two weeks after starting a course of the drug. Mr Williams will now call on the Department of Health to undertake an urgent inquiry into the controversial anti-depressant, which is manufactured by GlaxoSmithKline and prescribed to millions of people around the world. Speaking at the inquest into the death of 56-year-old Mr Whitfield, the Brecon coroner said, ``I have grave concerns that this is a dangerous drug that should be withdrawn until at least detailed national studies are undertaken. ``It is my intention to write to the Department of Health and the Secretary of State to ask him to hold an urgent inquiry into Seroxat and consider whether it should be withdrawn from sale in the UK. ``I am profoundly disturbed by the effect this drug had on Colin Whitfield,'' he said. ``It is quite clear that Seroxat has a profound effect on the thinking process of anyone who takes it.'' Mr Whitfield, who was described as a protective and loving father,died after cutting both his wrists on August 29 last year. He had locked himself in the garden shed at his home near Brecon while one of his daughters was asleep nearby. Just 14 days earlier, his GP had prescribed him Seroxat to treat anxiety. His wife of 30 years, Kathryn, told the inquest, said, ``I don't believe this was a conscious decision, I don't think it was an intentional act. There was no way he was in his right mind when he did that. ``There was no note and no intent. Two days before he died, on his birthday when he was opening presents, he asked, `What more can I ask for than my lovely family?' ``And on the night before he died he did and said three things that indicated he was planning ahead.'' She added, ``It didn't fit the picture of who he was and we have no doubt that it was the drug that caused him to do it. ``What he did was so totally out of character - he was a very caring, very protective father and husband. He would be hating himself for what he has done to his family.'' Seroxat was originally licensed as a treatment for depression but its use has now been expanded to cover obsessive compulsive disorder, panic disorder, anxiety and posttraumatic stress. But while it has proved successful for many users, manufacturer GSK is facing the prospect of legal action from users and their families on both sides of the Atlantic amid claims the drug is addictive, and can prompt suicide and violent and aggressive behaviour. Cardiff-based solicitors Hugh James, which is leading the action in the UK, is representing 4,000 people who claim they have been adversely affected. The inquest heard that concern about the safety of the drug has increased since June 2001 when a jury in the US ordered GSK to pay $6.4m to the relatives of 60-year-old Donald Schell who killed his wife, his daughter and granddaughter before turning a gun on himself in 1998 in Wyoming. He had been taking Paxil - the American name for Seroxat - for just two days. Since it was licensed for use in the UK in 1990, almost a quarter of all reports of fatalities from licensed medicines made to the Medicines Control Agency related to the use of Seroxat, said Mr Williams. And a third of all adverse incidents reported by doctors as part of the yellow card reporting scheme between 1991 and 1997 related to the use of the drug. Clinical studies into Seroxat - a second generation selective serotonin re-uptake inhibitor (SSRI) - have found a higher risk of suicide or attempted suicide in patients on the drug compared to other SSRIs or a placebo, and healthy volunteers have dropped out of similar Seroxat studies because of the onset of suicidal thoughts and tendencies. Research has also indicated that Seroxat, classed as a psychotropic drug, can cause ``emotional blunting'' in some people, meaning they are more likely to act on thoughts they would normally dismiss. In written evidence to the inquest, UK Seroxat expert Dr David Healy, director of the North Wales department of psychological medicine, said SSRIs caused a series of conditions which can increase the risk of suicide and it was common to find that people who are prescribed the drugs say they are ``simply not bothered any more'' and engage in ``out of character behaviour''. And his report said, ``Based simply on the research done and the figures available, and without close consideration of Mr Whitfield's case, there are good grounds to say an individual can commit suicide during the early time frame on an SSRI, but that individual is unlikely to have formed a consent to commit suicide in the normal fashion.'' In deciding to record an open verdict into Mr Whitfield's death, Mr Williams said, ``I have a picture of a kindly, gentle, courteous family man whose primary concern was his wife and children. But on this day he didn't care. ``He did a deliberate act affected, I have no doubt, by the taking of Seroxat.'' In a statement from Glaxo -SmithKline, a spokeswoman last night said, ``GSK offers its sincere condolences to the family of Colin Whitfield. ``As yet we do not have any official information from the court as the coroner is still sitting. ``We take the reporting of adverse events very seriously. The safety of all medicines is continually monitored by both GlaxoSmithKline and the Medicines Control Agency. ``Fortunately, with Seroxat we have a wealth of positive experience involving thousands of physicians, millions of patients and over 10 years of experience world-wide. ``There is no valid scientific research or literature finding that Seroxat causes suicidal thoughts or acts. Suicide can be a recognised component of depression. ``Fifteen per cent of all those suffering from depression eventually commit suicide. About 70% of the 4,000 suicides a year in Britain are people suffering from depression. ``We believe in the safety profile of Seroxat and will vigorously defend the integrity of our medication.'' Publication: The Western Mail Distributed by Financial Times Information Limited <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>

06 Март,2003 | Гениальность и помешательство - Чезаре Ломброзо

06 Март,2003 | Mania indication sought for Seroquel in Europe - Bipolar Disorder

AstraZeneca has submitted an application to the 14 European Member States involved in the Mutual Recognition Procedure for Seroquel to be granted a license for the treatment of manic episodes associated with bipolar disorder . Medical Letter on the CDC & FDA via NewsEdge Corporation : AstraZeneca has submitted an application to the 14 European Member States involved in the Mutual Recognition Procedure for Seroquel (quetiapine) to be granted a license for the treatment of manic episodes associated with bipolar disorder (manic-depressive illness). The Type II license variation application to Seroquel's existing schizophrenia marketing authorization means that the drug is now currently under regulatory review for bipolar mania both in Europe and the United States. "We are delighted to be submitting our application to the European health authorities so soon after our submission to the FDA" commented Geoff Birkett, global vice president, CNS, pain and infection. "Seroquel is a truly unique compound and its profile is ideal for the treatment of manic episodes associated with bipolar disorder. Use of Seroquel has been growing at a tremendous rate in Europe and feedback from patients and clinicians continues to be very positive. With its expanded indication range we are sure of further strong growth in 2003 and beyond." The application to the European health authorities follows the completion of a comprehensive bipolar disorder clinical trial program undertaken by AstraZeneca to examine the efficacy and tolerability of Seroquel in this important disease area. The program has delivered strong and positive results in both monotherapy and adjunctive therapy studies, which confirm Seroquel to be an ideal first-line agent in the treatment of manic episodes associated with bipolar disorder. The trial program consisted of four double-blind, randomized trials, involving almost 1000 patients in 28 countries. The trials assessed the effectiveness and safety of Seroquel as both monotherapy and adjunctive therapy with mood stabilizer in the treatment of manic episodes associated with bipolar disorder. "Seroquel as a treatment for bipolar disorder will offer significant benefits to European clinicians and patients," said Dr. Eduard Vieta, director of research, department of psychiatry, University of Barcelona. "Throughout the duration of the studies, Seroquel was shown to provide a substantial resolution of the various symptoms associated with manic episodes, while keeping side effects to a minimum. This is particularly critical in bipolar disorder since patients may lead full and productive lives when stable while a relapse in symptoms can cause real difficulties." Seroquel has been simultaneously submitted to the 14 European Member States participating in the Mutual Recognition Procedure. Further submissions in other markets worldwide are progressing. Seroquel is manufactured by AstraZeneca and is currently approved in more than 75 markets. Seroquel combines broad-based efficacy in the treatment of positive, negative, cognitive and affective symptoms of schizophrenia, while offering excellent tolerability. Seroquel is associated with an incidence of EPS and prolactin elevation no different to placebo across the full dosage range, a favorable weight profile, and no clinically important effects on QT interval in most patients. This article was prepared by Medical Letter on the CDC & FDA editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>

05 Март,2003 | New safety information associated with the use of ZOLOFT(tm) in patients taking pimozide

KIRKLAND, QC, March 5 /CNW/ - Pfizer Canada Inc. in consultation with Health Canada has informed Canadian health care professionals of clinically important new safety information concerning ZOLOFT capsules, a drug prescribed by physicians to relieve symptoms of depression, panic disorder or obsessive-compulsive disorder. Canada Newswire English via NewsEdge Corporation : KIRKLAND, QC, March 5 /CNW/ - Pfizer Canada Inc. in consultation with Health Canada has informed Canadian health care professionals of clinically important new safety information concerning ZOLOFT (sertraline hydrochloride) capsules, a drug prescribed by physicians to relieve symptoms of depression, panic disorder or obsessive-compulsive disorder. Based on the result of a recent clinical study, the concomitant use of ZOLOFT and pimozide (an anti-psychotic medication) is now contraindicated. Patients are advised not to take ZOLOFT with pimozide as their interaction may result in arrhythmias (irregular heartbeats), which may be serious and life- threatening. Patients should be aware that the symptoms of possible arrhythmia include dizziness, palpitations and fainting, and that they should seek immediate medical attention if these symptoms occur. If you are presently being treated with this drug combination, please consult your physician before changing your current therapy. This advisory is in addition to a letter issued to health care professionals reminding them of the above-mentioned safety information. As well, the product monograph for ZOLOFT is being revised to inform physicians regarding potential adverse effects this drug combination may cause. If patients have questions regarding their current prescription, they are asked to contact their physician or pharmacist. VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=56403 -0- 03/05/2003 /For further information: please contact: Rhonda O'Gallagher, Senior Manager, Corporate Affairs, Pfizer Canada Inc., (514) 693-4090/ CO: ST: IN: SU: CNW 17:39e 05-MAR-03 <> << Copyright ©2003 Canada NewsWire >>

04 Март,2003 | Пополнение в разделе Пособия

04 Март,2003 | Современное учение о неврозах - Пауль Шильдер, Освальд Бумке

Современное учение о неврозах - Пауль Шильдер, Освальд Бумке

27 Февраль,2003 | Hersh & Hersh Targets Eli Lilly's Most Profitable Anti-Psychotic Drug

27/02/2003 - Hersh & Hersh Targets Eli Lilly's Most Profitable Anti-Psychotic Drug SAN FRANCISCO--(BUSINESS Representing Numerous Plaintiffs, Attorneys Aim to Enforce Prominent Labeling of Zyprexa's Acute Side Effects Business Wire via NewsEdge Corporation : SAN FRANCISCO--(BUSINESS WIRE)--Feb. 27, 2003-- Representing Numerous Plaintiffs, Attorneys Aim to Enforce Prominent Labeling of Zyprexa's Acute Side Effects Hersh & Hersh of San Francisco (www.hershlaw.com) today announced that it has already filed several complaints on behalf of plaintiffs across the U.S. against Indianapolis-based Eli Lilly & Co. Attorneys are in the process of filing numerous other complaints and plan to prove that as a result of taking Zyprexa, a drug prescribed for the treatment of schizophrenia and bipolar mania, their clients have sustained life-threatening or fatal injuries, including diabetes mellitus, hyperglycemia and pancreatitis. In some cases patients have died after long-term use of Zyprexa, even though it has been FDA-approved only as a short-term treatment, and their families have hired Hersh & Hersh to represent them in wrongful death suits against the giant drug manufacturer. Cases are being filed individually, in both Federal and State courts. According to Hersh & Hersh partner Nancy Hersh, "Eli Lilly's profits are skyrocketing from these 'atypical' anti-psychotic drugs, while patients are being kept in the dark about their damaging side effects. We believe Eli Lilly is culpable in heavily promoting Zyprexa as a safe and effective drug for psychotic disorders, yet virtually concealing the risks to doctors and their patients." Evidence of Fatal Side Effects Exposed Since 1996 Eli Lilly has widely promoted Zyprexa as the most effective medication on the market for bipolar disorder, with fewer adverse side effects than any other methods of treatment. It is also the company's top-selling drug, with reported sales of $3 billion in 2001. However in 2002, author of Mad In America and medical journalist Robert Whitaker exposed clinical trial data about Zyprexa that was not made available to most doctors prescribing the drug. According to Whitaker, "Of the 2,500 patients in the trials who received Zyprexa, 20 died; 20 committed suicide; and 22% suffered a 'serious' adverse event. Two-thirds of the Zyprexa patients did not successfully complete the trials..." In July 2002, a team of medical researchers at Duke University discovered the link between the new generation of anti-psychotic drugs like Zyprexa and early onset diabetes. They identified 289 cases of diabetes in patients who had been prescribed Zyprexa, stating, "Of the 289 cases of diabetes linked to the use of Zyprexa, 225 were newly diagnosed cases; 100 patients developed ketosis (a serious complication of diabetes); 22 people developed inflammation of the pancreas, a life-threatening condition; and 23 people died. Over 70% of these cases occurred within six months of starting the drug treatment." Numerous other medical studies have reported that Zyprexa can result in serious -- and oft-fatal -- diabetic diseases, caused by severe insulin deficiency. In one Hersh & Hersh case, the North Carolina plaintiff suffered a diabetic coma after taking Zyprexa for eight months, and had to have his left leg and right foot amputated. In spite of these dangerous side effects there is no warning in Zyprexa's product information to monitor blood glucose levels, or discontinue use if high blood sugar is noted or if the patient develops diabetes. Currently, the literature accompanying Zyprexa only alludes to diabetes and acidosis as part of a list of side effects that are purported to be very rare. In the early 1980s Hersh & Hersh began working on DES cases and was the first law firm in the Bay Area to successfully beat Eli Lilly on behalf of DES children. Today Hersh & Hersh is suing Eli Lilly for failing to adequately disclose the serious side effects of Zyprexa, and for not ameliorating the cause of these injuries even though they were "scientifically knowable" at the time of distribution. Off-Label Drug Use is Growing Problem Among the numerous cases to be filed by Hersh & Hersh attorneys, several individuals were prescribed Zyprexa for the treatment for "off label" symptoms, including anxiety and depression, even though it is FDA-approved exclusively for schizophrenia and bipolar disorder. At least one client so far has developed an irreversible neurological disorder known as Tardive Dyskinesia and is subjected to a life of repetitive, rhythmic involuntary movements such as tongue thrusting, lip smacking, chewing movements, rocking of the trunk, marching in place and repetitive sounds such as humming or grunting. Zyprexa is among a host of anti-psychotic drugs that doctors are encouraged to prescribe for off-label uses by manufacturers. According to an article published last summer in The Globe & Mail (August 13, 2002), medical ethics professor Miriam Shuchman, MD, stated that the biggest difference between the approved and unapproved use of a drug is the evidence that backs it up. To get a medical condition approved or "on-label," drug companies must convince the FDA that high-quality studies show that the drug makes a real difference for people with that condition. Off-label uses of a drug typically have not been subjected to that level of scrutiny. "To boost sales and circumvent the FDA approval process drug manufacturers like Eli Lilly are actually encouraging their sales reps to push secondary uses of these anti-psychotic drugs and regularly review reports of the frequency of doctors prescribing these meds for off-label uses," added Hersh. "In many cases, off-label sales account for the bulk of revenues generated by these drugs. Our intention in the case against Eli Lilly is to also shine a light on the severe damage caused by this kind of dubious sales and marketing practice." About Hersh & Hersh Hersh & Hersh is a San Francisco-based law firm dedicated to protecting the safety and rights of consumers. The law firm represents clients both on an individual level and in class and multi-district litigation, and has pursued and won a wide range of civil suits, from product liability, medical malpractice and insurance bad faith to sexual harassment and employee discrimination. For the past 32 years, Hersh & Hersh has been committed to using the law to protect individuals by making sure companies exercise due diligence in manufacturing their products and operate in good faith in delivering their services. CONTACT: Hersh & Hersh Shelly Gordon, 650/856-1607 (Press) sgordon g2comm.com or Lisa Byrne, 415/221-5018 (Press) lisa lisabyrne.com KEYWORD: NORTH CAROLINA INDIANA CALIFORNIA INDUSTRY KEYWORD: E-COMMERCE INTERNET LEGAL/LAW PHARMACEUTICAL GOVERNMENT CLASS ACTION LAWSUITS PRODUCT SOURCE: Hersh & Hersh Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com <> << Copyright ©2003 Business Wire >>

26 Февраль,2003 | Общая психопатология - Карл Ясперс

| Главная | Структура центра | История НЦПЗ | Совет молодых ученых | Костромские школы молодых ученых | Новости | Профсоюз | Правовые документы | Вакансии | О сайте | Научная работа | Научные отделы и лаборатории | Публикации сотрудников | Диссертационный совет | Авторефераты диссертаций | Музей НЦПЗ | Для научных сотрудников НЦПЗ | Центр коллективного пользования «Терапевтический лекарственный мониторинг» | Образовательная деятельность | Ординатура | Аспирантура | Дополнительное профессиональное образование | Студенческий научный кружок | Нормативные документы | Платные образовательные услуги | Информация для обучающихся в ординатуре и аспирантуре | Лечебный процесс | Клинические отделения | Условия и порядок стационирования | Прейскурант платных медицинских услуг | Перечень заболеваний | Отзывы о работе клиники | Клиника (фотогалерея) | Библиотека | Научная литература для специалистов | Материалы конференций | Авторефераты диссертаций | Пособия для врачей | Психометрические шкалы | Болезнь и творчество | Галерея | Журнал «Психиатрия» | Перечень тематических журналов, рекомендованных ВАК | Перечень тематических журналов в международных БД | РИНЦ | Russian Science Citation Index (RSCI) | Полезные ссылки | Журнал «Психиатрия» | Неспециалистам | Контакты